Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  García Cruz, Eduardo ^a   Piqueras, Marta ^a   Huguet, Jorge ^a   Peri, Lluis ^a   Izquierdo, Laura ^a   Musquera, Mireia ^a   Franco, Agustin ^a   Alvarez Vijande, Ricardo ^a   Ribal, Maria Jose ^a   Alcaraz, Antonio ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Prognosis factors; Prostate cancer; Testosterone levels

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TUMOR MARKER;

AGE; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; BIOPSY; BLOOD; CANCER GRADING; COMPARATIVE STUDY; DISEASE COURSE; FOLLOW UP; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; RISK FACTOR;

AGED; BIOPSY; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM GRADING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84876421876     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11232.x     Document Type: Article

References (23)

1. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209-23
2. Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 1942; 115: 1192-200
3. Isbarn H, Pinthus JH, Marks LS et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009; 56: 48-56
4. Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276: 1904 - 6
5. García-Cruz E, Huguet J, Piqueras M et al. Low testosterone bioavailability is related to prostate cancer diagnosis in patients submitted to prostate biopsy. World J Urol 2011; doi:10.1007/s00345-011-0741-9 [ Epub ahead of print ]
6. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006; 68: 1263-7
7. Isom-Batz G, Bianco FJ, Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005; 173: 1935 - 7
8. Imamoto T, Suzuki H, Fukasawa S et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 2005; 47: 308-12
9. Massengill JC, Sun L Moul JW et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169: 1670-5
10. Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology 2008; 72: 1240-5
11. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163: 824-7
12. Schatzl G, Madersbacher S, Thurridl T et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001; 47: 52-8
13. Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 2005; 174: 2178-80
14. Yamamoto S, Yonese J, Kawakami S et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007; 52: 696-701
15. Stattin P, Lumme S, Tenkanen L et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004; 108: 418-24
16. Morote J, Ramirez C, Gómez E et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. B JU Int 2009; 104: 486-9
17. Sofikerim M, Eskicorapci S, Oruç O, Ozen H. Hormonal predictors of prostate cancer. Urol Int 2007; 79: 13-8
18. Yano M, Imamoto T, Suzuki H et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol 2007; 51: 375 - 80S
19. D ' Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74
20. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
21. Morgentaler A. Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol 2007; 52: 623-5
22. Morgentaler A. Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer. J Sex Med 2008; 5: 1834-40
23. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006; 50: 935-9